- js reader version
- view hidden posts
- tags and related articles
by Alex Constantine
Tuesday, Nov. 23, 2004 at 4:56 PM
Aids and the weaponized AMES strain anthrax mailings of 2001 are both creations of scientists at SAiC-USARMIID, Ft. Detrick. BioPort, Bayer and VaxGen manufacure anthrax "vaccine" - what we've seen this far is contaminated and ineffective against the Ames strain - and each has a roots in Nazi Germany and have their own histories of illicit human experimentation.
Part XXV(F): PROJECT ANTHRAX - VAXGEN’S DR. DONALD FRANCIS, CO-CREATOR OF AIDS
& THE NEUORDNUNG’S EMERGENT VIRUSES
By Alex Constantine
SAIC’S Colonel David Franz was a cheerful “counter-terrorist.” He told ABC News on April 4, 2002 that a “lot of good” had come of the anthrax attacks. Sad Sacks and Dreary Donnas may tremble because “five people have died, but we’ve put about billion in our budget.” Thumbs up. A sunny disposition can carry one far in the military heirarchy. Dr. Franz was appointed to the Homeland Security Science and Technology Committee in February 2004 by Dr. Charles E. McQueary (former president of General Dynamics), undersecretary for science and technology at the Department of Homeland Security.
Biological threats loomed on the horizon, the Pentagon’s viral visionaries assured with psychic certainty. Peculiar, though ... read the small print on the packaging and it’s clear that the newly emerging diseases and the vaccines created to repel them hung in ... CLUSTERS.
Ingri Cassel comments, “Cipro and smallpox vaccine have much in common besides capturing America's urgent attention.” Alas, the corporate parents of the companies that produce “these favored elixirs for anthrax and smallpox bioterrorism are linked, strangely enough, to an infamous history involving contaminated blood, the Central Intelligence Agency (CIA), and even the Nazi [ties] that the FBI doesn't seem anxious to explore.”
Cipro is manufactured by Germany's Bayer AG, and “the smallpox vaccine's newly formed producers are Acambis [formerly OraVax, the West Nile people]. ... All have jaded histories. The ‘Big Three’ - Bayer, Baxter, and Rhone-Poulenc - are infamously known for having infected more than 7,000 American hemophiliacs with the AIDS virus during the early 1980s. They admitted foreknowledge in selling HIV-tainted blood clotting products and settled the class action case for 0,000 per claimant.”1
Two shrouded power bases of the Third Reich, Bayer and Hoechst, were spun from IG Farben following World War Two. Hermann Schmitz, president of Farben during the war (which had partial control of the Deutsche Bank) “held as much stock in Standard Oil of New Jersey as did the Rockefellers,” according to author Paul Manning. He wrote that on August 10, 1944, the Rockefeller-Farben group filtered flight capital through “affiliated German/French, American, British and Swiss banks ‘for the new Germany.’” The reserves secured "the sophisticated distribution of national and corporate assets to safe havens" across the globe, ensuring the continuation of the "Neuordnung (New Order)” for the petrochemical, drug and banking cartels.2
An upcoming distiller of the said “elixirs,” joining BioPort and Bayer, is VaxGen (owned by Genentech ((55.6%-owned by by Hoffmann-La Roche (((owned by Roche AG of Switzerland, also an ally of Farben and the German Reich))).
In November 2004, the company publicized a contract under the auspices of Project BioShield worth 7 million over five years, with the government paying VaxGen to produce 75 million doses of anthrax vaccine. In addition, the company is to receive 3 million in further payments from the government in late 2007.3
And it’s just one more well-hyped boondoggle if the history of AidsVax, the company’s failed HIV drug, is any indication.
On October 3, 1999, the Times of London reported that before VaxGen went public, “the most important government cheerleader for AidsVax” - Dr William Heyward, head of HIV vaccine research at the CDC - “had a SECRET DEAL to join the company.” From the CDC, Dr. Heyward “lobbied policymakers and approved million in grants for VaxGen. But the company had already drawn this chart on his future duties, and in January 2000, he joined ex-CDC staffer Dr. Donald Francis, VaxGen president, who also hired former CDC deputy director Dr Walter Dowdle to head its influential data monitoring board.”
In US v William L. Heyward, prosecutors charged him with violation of anti-graft laws. Dr. Heyward skipped up the corporate ladder to a VP’s office at VaxGen, but eventually confessed to the flagrant conflict of interest, paid a ,500 fine “and escaped a high-profile criminal trial that might have proved devastating to the AidsVax project,” the Times reported.
Next thing you know, on March 17 2003, a class action lawsuit was thrown at VaxGen. The suit claimed securities fraud after Dr. Heyward wrote a series of glowing reports on the potential of AidsVax that inflated the stock price but proved baseless when the drug failed its clinical trials.
A word about those “trials”: As we shall see, there was little that was “clinical” about them. Testing of the vaccine was sponsored by the NIH, FDA, World Bank, UN agencies and the International Aids Vaccine Initiative.4
The tests were overseen by Dr. Donald Pinkston Francis, president of VasGen, who, along with molecular biologist Dr. Philip Berman, founded the company in 1995. Dr. Francis, 62, was bestowed with an honorary Doctor of Science degree from Harvard in 1979. Since 1978, he has been chief of the epidemiology division at the Hepatitis Labs Division of the CDC. Under the auspices of the Agency for International Development (AID), he served as an epidemiologist in Rivers State, Nigeria (1971). He was American “epidemiological intelligence service officer” at the CDC (1971-73).(In And The Band Played On, Randy Shilts's 1987 Aids book, Dr. Francis is found on no less than 76 pages, a driven, scolding, at times hysterical presence. In the movie, he's played by Full Metal Jacket's Matthew Modine.”5)
Dr. Leonard Horowitz, an indepenent authority on public health education and the origins of AIDS, writes that Dr. Francis had “intimate connections to the U.S. Government agencies, programs and people (including Max Essex and Robert Gallo) that CREATED numerous AIDS-like and Ebola-like viruses during the ‘Special Virus Cancer Program’ of the late 1960s and early 1970s...”6
Dr. Francis is one of the instigators of Aids, as Horowitz deconstructs the history of the disease
under the Neuordnung.7
The London Times detailed the “clinical trials” conducted by Dr. Francis’s team in Thailand. As Dr. Heyward sees it, "only through such trials will further knowledge be gained". Thumbs up.
AIDSVAX: THE VAXGEN EXPERIMENT
The Sunday Times Magazine (UK)
October 3, 1999
By Brian Deer
... At first glance, Thailand is a strange location to carry out medical trials.... Corruption is de rigeueur, while police are accused by Amnesty International of "extra-judicial killings". Much of its profile relies on sex: first with young women and later with children.
Since the coup, however, quick cheap, experiments on the Thai population have been added to the country's attractions. Dozens of projects are currently in progress, run by foreign pharmaceutical companies and sponsored by the CDC and WHO. With an estimated 800,000 Thais infected with HIV, Aids is the big one, with tests of drugs, immune-system stimulants, and top of the list Francis's AidsVax trial.
It makes sense to test products where the risk of Aids is greatest, but my attention was drawn to potential problems during a conference in a Bangkok hotel. The topic was Aids vaccines. Francis spoke. And a doctor pointed out that some volunteers in an AZT trial were mothers from remote hill tribes. “They come across the border from Burma.” he said. "They don't speak Thai, so there is the question of whether they can understand enough to give informed consent."
The question was brushed aside ("They keep coming back.") and might not have meant much if I hadn't also met an activist from the northern town of Chiang Mai. Despite grilling 11 people who swallowed tablets daily, he complained that he couldn't discover even the name of the product or the pharmaceutical company involved. This man was a former heroin user, so I asked him where VaxGen was recruiting. "Go to Khlong Toei," he said. "By Port Authority Building. That's where they'll get people for the trial."
Khlong Toei is a slum; a sewage-stinking wasteland; a cauldron of disease and drug use. The better-off live in concrete hutches, with wire-fenced windows and balconies. Next down in the social scale are wooden-shack coops on plots of flood-prone ground. Then there are kennels: festering shantytown alleys of plank, sheet-iron and debris sheds. The "streets" are dim corridors, with boardwalk floors, cluttered with children and dogs. At night frail figures shuffle around, suffering from Aids, tuberculosis or both.
Thailand was once praised for anti-HIV efforts in disease hot zones such as this. But evidence suggests that since the 1992 coup priorities have changed. In 1992, a health minister complained that talk about the virus had "seriously affected tourism". And now, official figures show that Aids prevention has been slashed by one third against comparable public health programmes.
The biggest cuts have been in initiatives aimed specifically at drug misusers. "There used to be a project for clean needles in the early 90s, but now it's gone," a spokeswoman for a Khlong Toei charity, the Duang Prateep Foundation, told me....
Nobody could explain the thinking, but the effect on the junkies can be measured. Blood tests reveal that HIV prevalence peaked among female prostitutes in 1993 - when 30% were positive - and has since fallen back to 21%. Among rent boys, prevalence peaked in the following year at 18%, and is now half that figure. But prevalence among heroin-injectors has leapt from 31% in 1994 to a staggering 47% now.
Were these changes evidence that the government were allowing the junkies to be put at greater risk to make them useful for experiments? (Health department officials told me that if AidsVax is marketed, they expect a billion-dollar manufacturing plant.) I couldn't find out. People wouldn't talk when I raised such contentious concerns. Even Bangkok's Medicines Sans Frontieres staff went silent when asked about the trial.
Francis is convinced that nothing is amiss, and his collaborators voice no worries. "All have assured me that this has been done ethically," he told me, when eventually we met. "We are going out of our way not to increase the vulnerability of an already vulnerable population." The trial was conducted in Thailand, he said, for scientific reasons. Different parts of the world are linked with different HIV subtypes, with their myriad subsidiary strains. B subtype strains, for instance, are most common in North America, Europe and Australasia; A, C and D in Africa. In Thailand, there's a mix of B and E strains and, for technical reasons to do with E strains, the company argues that success is more likely there "than anywhere else in the world."
But there are aspects of the project which suggest that the junkies may be involved in an unusual way. A parallel trial among gay men at American clinics is having problems finding and keeping volunteers, due to scepticism towards the venture. But at Kachit's clinics the programme has features which may help to avoid these snags. The junkies get methadone, an oral heroin substitute, plus expenses for each of up to 17 visits. The risk is the appearance of offering drugs and money as inducements to this desperate group.
There's also a feature of the experiment's design that seems self-contradictory. If the methadone liquid got people off injecting heroin, the volunteers' risk of infection would slump and they would be of little use to the vaccine trial. In fact, documents drawn up with the CDC and WHO show that that 7% of clinic users are expected to become HIV-infected each year. So, despite the oral methadone, they keep injecting heroin. They may even buy it with VaxGen's money and have an increased risk of getting Aids.
The logic of the trial creates a dilemma for Francis. The moral uncertainties about using junkies as GUINEA PIGS might be offset by humanity's greater needs. But there would need to be plausible scientific grounds to think that AidsVax might work. And on that the VaxGen experiment is open to even greater doubts.
When Francis returns from his trips to Bangkok, it's to Brisbane, a community on the San Francisco peninsula, midway between the city and its airport. His home and workplace both looks eastward across the bay: towards Oakland and, beyond that, America. His home is on a hill and lined with Chinese paintings. His office is by the shore, in black glass.
He huddles weekly with his senior colleagues: VaxGen's vice-president, Dr Phillip Berman, and its chairman, Dr Robert Nowinski. Berman, aged 49, is a molecular biologist. He's heavy set with curly hair and has laboured on the science for 15 years. Nowinski, 52, is bald and wears glasses. He's a biotechnology entrepreneur from Seattle. His main claim to fame is having founded and sold a company, ICOS, which boasts Microsoft's Bill Gates as an owner.
The key document at many of their sessions is a "special issue" of a prestigious journal, called Aids Research and Human Retroviruses. It's dated last October. Twenty papers are inside and they're a rave for VaxGen's ideas. Dr Seth Berkley, the International Aids Vaccine Initiative's president, declares that politics and economics are bigger obstacles to progress than "a scientific barrier". Dr Mary Lou Clements-Mann, a researcher for a rival company's vaccine (and who died in a Swissair plane crash off Nova Scotia last year), shrugs off pessimistic "misperceptions". ...
When visitors drop by, Berman outlines his own paper. It sets out how AidsVax is meant to work. "Many lines of evidence suggest that a strong antibody response to the HIV-1 envelope glycoprotein," he explains, "will be an essential feature of any Aids vaccine." Berman sketches what this means on a board in the conference room, across the corridor from Francis's office. The billions spent on Aids have produced unparalleled insights on HIV, which are the platform on which he builds. The virus infects. The immune system checks it with, among other things, specially-tailored antibodies. But the virus mutates around these adversaries. So the immune system tailors new defences. The virus then mutates and immunity responds. It's like a leapfrog competition. Eventually, the immune system tires of all this leaping, packs up and then it's Aids.
Of all the different parts of HIV, the envelope glycoprotein gp120 is the part that mutates the most. This sits in blobs around the virus, like loose balls of wool, on the tips of protruding spikes. Berman zooms on the moment a blob meets a cell, which is 1m times bigger than the virus. Part of the blob's surface locks onto a receptor (like a data-port where cells get information). The blob then unravels and locks another of its parts onto a second sort of receptor on the cell. This cues the cell to pull the virus inside. Infection is complete.
Here, Berman argues, is where AidsVax helps: by blocking this double-lock connection. Summoned in advance, due to earlier vaccination, antibodies stick to key parts of the blob and so stop it from locking on the cell. If the virus is a burglar, these antibodies are bullterriers, waiting for a leg to appear through the window on which to snap their jaws. Once they've got hold, the virus is paralysed, to be disposed of by other kinds of cell.
He makes things sound simple. Visitors are impressed. Investors wonder: why dither in Bangkok? But the science expounded in the journal issue doesn't convince many people who grasp the detail. "It's a waste of time," Dr Robert Gallo, America's pre-eminent retrovirologist, told me. Prof Andrew McMichael, Aids vaccine chief at Oxford's Institute of Molecular Medicine, said: "I wouldn't have the belief that this will work." And Dr Jean-Paul Levy, head of France's vaccine programme, spat: "It forgets one century of science."
For all the plausibility of the journal's special issue, the most detailed analysis of VaxGen's approach was published in February last year in the Journal of Virology, an even more influential publication. More than 500 people - mostly American gay men - took part in preliminary tests of gp120 in the mid-1990s but experts at seven of America's leading research centres found that, despite the shots, 16 vaccine recipients became infected with HIV. That's more than 3% of those getting vaccine, roughly the same percentage as those on placebo.
Molecular biologists were not surprised, although their critique is extremely technical. What it boils down to is that if HIV leapfrogs the immune system - with all its astounding complexity - it will easily do the same with antibodies induced by an off-the-shelf manufactured product. Inducing antibodies to one B strain, or two E strains, or five, or fifty XYZ strains, is like buying insurance against being hit by cars with specified license plates.
VaxGen's answer is to develop products from strains it claims provide "cross-protection" against others. In Bangkok, for instance, the vaccine is AidsVax B/E, including gp120 clones from one B and one E strain. The B strain was isolated from a six-year-old New Jersey boy in 1984, while the E strain was collected from a soldier in Chiang Mai about nine years ago. The plan is to mix 'n' match vaccines in this way to suit the subtypes in different parts of the world. Berman zooms closer and claims that parts of gp120 stay sufficiently constant between the mutating strains to offer a point of attack. Like all proteins, the blob is made from amino acid molecules, which string together like beads in a necklace to make the loose balls of wool. Each bead is made from one of a possible 20 amino acids. Letters are used to denote these acids: G stands for glycine, for instance, R for arginine and Q for glutamine.
Berman says that the vaccine needs to copy the amino acid sequence at a key point in this string. Near to where gp120 locks onto the cell, there is a loose loop of "wool" - not 100 millionth a cell's size - which biologists call V3. Berman zooms again: to the tip of this loop, a string of just six necklace beads. Here, he argues, is a segment that remains more constant than most and induces antibodies which will stick and stop the double-lock connection with the cell. All it needs is for the vaccine and the virus to have the same acids at the tip of this loop.
Using this argument, Berman deduces that the early tests of gp120 offer hope for the experiment after all. Mostly, volunteers studied for the Journal of Virology were injected with gp120 cloned from the New Jersey strain, in which the necklace in the V3 loop's tip has the beads GPGRAF (meaning: glycine, proline, glycine, arginine, alanine, and phenylalanine). It's a common configuration in North American strains. But Berman argues that some of the volunteers who became HIV-positive despite being vaccinated were infected with strains in which the loop was different: say, GPGRVL (ending with valine and leucine instead). This, he suggests, was why the gp120 didn't protect them. With the commoner strains he believes it did.
At VaxGen's offices, this bottom-line is dazzling. The "special issue" paper quickens pulses. But additional information reveals an oddity, which Berman's presentation overlooks. At the American government's Los Alamos National Laboratory, in New Mexico, staff track amino acid sequences for thousands of HIV strains. And when I asked them to print their data from Thailand, a startling contradiction emerged. The B component in AidsVax B/E - the shots being given to the junkies - has the New Jersey V3 loop tip sequence. It goes: GPGRAF.
According to Berman's argument, the local B strains would need to have the same string of beads. But only 10% of Thai B strains have the New Jersey amino acid sequence. Far more often - in nearly half the strains - there are two different beads in the loop's tip: glutamine (Q) and tryptophan (W). They are GPGQAW. By Berman's own reasoning, the Bangkok junkies are being injected with the wrong vaccine.
Every six months, a ten-strong committee of doctors and scientists crowds into VaxGen's boardroom. This is the "data safety and monitoring board", recruited to keep an eye on the experiment. On one side of the table sits a Harvard infectious disease specialist. On the other is a Yale ethicist. There are three Thai physicians and a Seattle statistician. Dr Walter Dowdle, a former CDC deputy director, presides. The Americans are casual, in open-necked shirts, but Dowdle runs proceedings with care. Piled around the table are printouts on the volunteers, with blood tests and other results. Using codes which nobody else gets to look at, they can see who's getting AidsVax and who the placebo and whether any difference the number of HIV infections has emerged between the groups.
By the convention for vaccines, any difference would be vast for the product to be declared effective. Measles vaccine, for instance, is 95% effective, tetanus 90%, and hepatitis B 85%. But the committee's brief is to watch for just 30% effectiveness. Such is the threat from Aids, it's argued, that this figure is enough for success.
I asked a professor of medical statistics to number-crunch this percentage. To reach the 30% mark, he said, there would only need to be 28 more infections among junkies on the placebo than among those receiving AidsVax. If VaxGen recruits 2,500 - and on its assumption that in a year about 7% (87 people) on placebo will become infected due to needle-sharing - then if the number who become infected after getting AidsVax is 59 (4.7%) or fewer, the committee can rule that the product works.
VaxGen critics think that even this meagre difference couldn't appear, and that Dowdle, 68, will one day emerge to drape a consoling arm on Francis's shoulder. But an alternative scenario is predicted by some with long research experience. Nobody can recall an HIV product being ditched after reaching a full-scale efficacy trial. And, such is the desire for "something to be done" about Aids that science could be pushed to one side.
The most powerful pressure for something to be done comes from the White House, anxious to appease the Aids lobby. In May 1997, President Clinton threw his weight behind urgent action. "If the 21st century is to be the century of biology," he declared. "Let us make an Aids vaccine its first great triumph."
How such pressures can translate date back to 1989 and the first anti-Aids drug, AZT. A board like Dowdle's monitoring a trial among HIV-positive volunteers with no obvious illness, saw data suggesting that full-blown Aids could be prevented. At the time, AZT was licensed only for terminal disease, but this finding caused the trial to be halted and the product to be approved for this use. But the decision was based on a transitory data "blip", which had caused the board to act prematurely. A longer study, published four years later, found no preventative effect.
Stopping trials in this way before their scheduled completion is now standard in Aids product development. "If efficacy is observed at the time of a scheduled interim efficacy analysis," Nowinski explains, "the monitoring board will recommend termination of the trial."
But could bodies such as the Food and Drug Administration and the European Medicines Evaluation Agency license a vaccine that doesn't work on the basis of an AZT-style blip? Evidence suggests that agencies under political pressure take just such paradoxical steps. The National Institutes of Health, for instance, vetoed the VaxGen experiment as a waste of money and volunteers. But after being accused of "a human rights violation" by Dr Jonathan Mann, 51, former WHO Aids chief (and who died with his wife, Clements-Mann, also 51, in the Swissair crash), the institutes not only reversed themselves, but granted Francis .6m.
Sometimes the clamour may be marshalled by persons who may not be as detached as they seem. The Journal of Aids Research and Human Retroviruses, for instance, has an editorial board that's a Who's Who of Aids. But Francis paid the publisher ,000 for the "special issue", which Berman edited as a "guest". As for some of the contributors, Francis helped to set up Berkley's international vaccine initiative and advised Bill Gates's charity foundation to give it m. He has done a deal to supply proteins to the rival manufacturer which employed Clements-Mann. And he has offered the CDC's Heyward the post of VaxGen vice-president, starting next January.
Pressure also comes from powerful bodies which have long-held institutional agendas. The CDC, which mostly collates disease data, first became a significant health service body due to polio vaccine, launched in April 1955. The WHO's singular success was smallpox eradication, accomplished in October 1977. Mass immunisation is what they know best. It's simply what they do. "Don Francis reminds them of when they were young," Dr John Moore, of New York's Aaron Diamond Aids Research Center, told me.
What worries critics such as Moore is that political and institutional pressures may lead to millions of people being injected with AidsVax before the benefits and risks are clear. The WHO estimates that annual demand for the first vaccine will be 650m doses and UNICEF leaders are thinking about adding it to programmes for 100m children.
Francis anticipates that the CDC, which has already granted him m, is to finance a US immunisation campaign and, in Europe, national health services will pick up the tab. "In addition, the International Aids Vaccine Initiative has started a campaign to fund the development and purchase of an HIV vaccine for the developing world," VaxGen documents say. "In meetings with us, the World Bank has indicated that it's exploring the potential for low-interest loans to support the purchase."
One of the snags which may be overlooked in this rush is the effect on recipients' behaviour. Common sense says that somebody who thinks that they may be protected is more likely to take chances with risky activities than a person who knows that they aren't. One study of this effect in 1997 found that unsafe sexual behaviours doubled among gay men in preliminary vaccine tests. If this was repeated globally, the impact of an even vaguely effective AidsVax may be that the Aids epidemic gets worse.
South of VaxGen's offices, the next freeway exit gives access to its powerhouse: Genentech. This is the world's front-runner in medical biotechnology, with seven licensed products, from human growth hormones to a clot-buster, Activase. Twenty years ago the company was all dreams and venture capital; its few staff snipping and splicing genes in a wasteland where shipyards had died. Today, their ranks of Mercs and BMWs surround 26 buildings in biology's Silicon Valley.
Stopping by from time to time are visitors from its master, the druggernaut Hoffman-La Roche. With twin headquarters in Basle and New Jersey, and sales last year of SWf24.7bn (œ10.2bn), this vitamins-to-Valium giant has the marketing muscle should AidsVax come on stream. At its own labs, Roche shuns the vaccine race, but with taxes pledged to line-and-jab Africa and Asia executives doodle in billions on the hope that Francis pulls it off.
When I flew to San Francisco to quiz Francis for this story, Berman was ecstatic, in jeans and a check shirt, over a new .4m vaccine facility. The experiment produces a torrent of clinic samples; each volunteer gives blood on 17 visits, and each sample is split for tests. Giant freezers were being installed to store bar-coded specimens. There could be 400,000 in all. There's also a 0,000 microbiology kit going in: DNA sequencers, PCR machines, centrifuges and the like. Soon he would direct 30 staff in 20 rooms. He was like a seven-year-old on Christmas Day.
The first thing that struck me was the push of the spending, irrespective of scientific achievements. Apart from all the investment so far, Genentech had a 10,000-litre fermenting tank, half full of New Jersey strain vaccine. Nobody wanted that, worth m, flushed away, much less the careers of its makers. The next thing I noted was the standard of safety imposed on the facility's construction. To handle a dangerous pathogen in California, the brown-and-yellow building, made from tipped-upright concrete slabs, was stamped with certificates and permits by the box load before the first plank was sawn. It's both earthquake- and microbe-proof. And its forests of copper pipes, air ducts and bio-filters were tested to tolerances few structures could endure.
But while regulations make sure that the building is safe, critics say that the product itself escapes much rigorous scrutiny. With vaccines, any problems often don't appear until mass-market use, and such is the head of steam building up behind Francis that sceptics think that if AidsVax doesn't join the annals of useless shots, it has the potential to join, say, a 1960s measles vaccine that made the disease in those infected worse.
What worries some scientists is that because AidsVax provokes antibodies to its own specific gp120 strains, there's a risk that it may actually suppress the immune system's ability to combat other strains. On this thinking (the principle is sometimes called "deceptive imprinting") even if the junkies were protected against the New Jersey and Chiang Mai strains, they might die more quickly if they get infected with one of the countless other mutations. "There's nothing new in this," Dr Heinz Kohler, who has led investigations at Kentucky University, said. "It's just common sense."
At Kansas University, researchers have found that monkeys injected with gp120 and then a hybrid kind of HIV had more of the virus in their blood later on than infected animals which weren't vaccinated. "The question is: will those people who are vaccinated progress to Aids more quickly if they become infected with HIV than those who were not vaccinated at all?" Prof McMichael at Oxford summarised. "We might not know the answer for 10 years." ...
[TO BE CONTINUED]
1) Ingri Cassel, “Public Health Expert Says Solving The Anthrax Mailing Mystery May Be Easy: FBI Doesn't Seem Interested,” news release, Tetrahedron, LLC, Nov. 12, 2001.
2) Paul Manning, Martin Bormann: Nazi in Exile, Secaucus: Lyle Stuart, 1981.
3) Adam Feuerstein, “VaxGen Hits Anthrax Jackpot,” TheStreet.com, November 5, 2004.
4) Brian Deer, “AidsVax: The VaxGen Experiment,” Sunday Times Magazine (UK), October 3 1999.
6) Dr. Leonard Horowitz, ”New Genocidal AIDS Vaccine Experiments: Don Francis, Genentech, Hoffman-La-Roche, and The Rise of the Fourth Reich,” updated 11/07/02.
7) Ibid. Also see, A. Cantwell, AIDS and the Doctors of Death. 1988 (pp. 50-2, 78, 178), A. Cantwell, Queer Blood: The Secret AIDS Genocide Plot. 1993 (pp. 42, 109, 123).
Introduction by Dr. Len Horowitz
Report this post as:
Woolsey Fire: Worst News of 2018?
Oppose Environmentally-Harmful Development
Oppose Environmentally-Harmful Development
OUR HOUSE Grief Support Center Presents Night for Hope
Marshall Tuck’s racist dog whistle
Marshall Tuck’s ethnocentrism contradicts Californian values
Debunking Some Anti-Prop 10 Propaganda
Why Should California Choose De Leon Over Feinstein?
Change Links September 2018 posted
More Scandals Rock Southern California Nuke Plant San Onofre
Site Outage Friday
Change Links August 2018
Setback for Developer of SC Farm Land
More problems at Shutdown San Onofre Nuke
Change Links 2018 July posted
More Pix: "Families Belong Together," Pasadena
"Families Belong Together" March, Pasadena
Short Report on the Families Belong Together Protest in Los Angeles
Summer 2018 National Immigrant Solidarity Network News Alert!
More Local News...
Judge Delays Ruling on Puerto Rico Debt Deal White House Opposes Island's Food Assistance
Paraphysique de proxémie guerrière
DEAD MAN LIVING
DIARY OF A CON MAN
PR Debt Cancel, Judge Reviews Cofina Debt
Réseautage, fragmentation du capital
Paraphysique de manipulation mentale et sociale
The Global Justice Project and Human Survival: We're Badly Off Track
The Global Justice Project and Human Survival: We're Badly Off Track
The Global Justice Project and Human Survival: We're Badly Off Track
Markets as a Fetish, Globalization, and Dissent Management
State Debts - The Primal German Fear
Sans liberté, sans égalité, sans fraternité
From Progressive Neoliberalism to Trump - and Beyond
Copper Cures Cancer
Steven Taylor, Investor who Evicts
Du sectarisme, des sectes, des clans
“Animaniacs in Concert!” Starring Voice Legend Rob Paulsen
Patrick Kilpatrick discusses and signs Dying for Living
SexActs vs Sexuality USA 2018 Invitations to Power Marriages without Affection
Changer de mentalité, changer de société
Teacher Strike? Time for Labor Studies
December 2018 Honduras Coup Update
Paraphysique de la désespérance
More Breaking News...